Aziyo Biologics, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Aziyo Biologics, Inc. (NASDAQ: AZYO) develops, manufactures, and commercializes biomaterial-based regenerative products for orthopedic, spine, neurosurgery, trauma, and general surgery applications. The company offers a portfolio of differentiated allografts, including its flagship OsteoCove, which provides customizable bone void fillers in putty and fiber forms; SimpliDerm for soft tissue repair; ProxiFuse for proximal interphalangeal joint fusion; and other products such as Viance, In2, and BioBurst, all derived from human donor tissue processed through proprietary methods to support bone and soft tissue regeneration. These products target surgeons and healthcare providers in the U.S. market, with distribution through direct sales and partnerships. Founded in 2017 and headquartered in Silverdale, Washington, Aziyo operates primarily in the regenerative medicine segment of the biologics industry. In recent developments, the company completed a strategic business combination with the former Aytu BioPharma, Inc. in June 2025, adopting its current name and focusing on orthopedic biologics following a shift from broader therapeutic areas; additionally, it launched expanded product lines and secured distribution agreements to enhance market penetration.
Elutia to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Aziyo Biologics Announces Publication of a CanGaroo® Case Study Demonstrating Bioenvelope Benefits for Reoperative Procedures
Aziyo Biologics, Inc. (AZYO) Q2 2023 Earnings Call Transcript
Aziyo Biologics Reports Second Quarter 2023 Financial Results - Transformation Continues to Drug-Eluting Biomatrix Company
Aziyo Biologics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023
Aziyo Biologics Announces Voluntary Recall of Viable Bone Matrix Products
Aziyo Biologics, Inc. (AZYO) Q1 2023 Earnings Call Transcript
Aziyo Biologics to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
Aziyo Biologics, Inc. (AZYO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Aziyo Biologics, Inc. (AZYO) Q4 2022 Earnings Call Transcript
ACER's Stock Down on Failure of Phase II Study, Cash Updates
Aziyo Biologics to Report Fourth Quarter and Full Year 2022 Financial Results on Wednesday, March 22, 2023
Aziyo Biologics to Present at the Cowen 43rd Annual Health Care Conference
Aziyo Biologics, Inc. (AZYO) Upgraded to Buy: Here's What You Should Know
Aziyo Biologics to Participate in Upcoming Investor Conferences
Aziyo Biologics, Inc. (AZYO) Q3 2022 Earnings Call Transcript
Aziyo Biologics, Inc. (AZYO) Reports Q3 Loss, Tops Revenue Estimates
Aziyo Biologics to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase
Aziyo Biologics (AZYO) CEO Randy Mills on Q2 2022 Results - Earnings Call Transcript
Aziyo Biologics to Report Second Quarter 2022 Financial Results on August 11, 2022